Meta Expands AI Training With Employee Activity Tracking Tools 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
NEW YORK, March 31, 2017 -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Adnan Butt will join the firm as a Managing Director to expand Healthcare coverage on the Equities platform. Mr. Butt will join Guggenheim on the Healthcare research team in June, specifically focusing on biotechnology companies.
Mr. Butt joins Guggenheim from RBC Capital Markets, where he was a Biotechnology Analyst. Prior to RBC, he covered biotechnology at ThinkEquity Partners, Morgan Stanley, and J.P. Morgan & Co.
“We are excited for Adnan to join our team,” said Jerry Donini, Co-CEO of Guggenheim Securities. “His deep industry knowledge provides a significant expansion to our Healthcare platform, building on our existing research presence in specialty pharmaceuticals, major pharmaceuticals, biotechnology, and medical devices and supplies. We look forward to his success at Guggenheim.”
Mr. Butt received his M.A. in Economics from Trinity College and his M.A. in Neuroscience from the University of Hartford; he received his B.A. in Economic and Molecular Biology & Biochemistry from Wesleyan University. He will be based in Guggenheim’s San Francisco office.
About Guggenheim Partners
Guggenheim Partners is a global investment and advisory firm with more than $260 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With more than 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.
1 Assets under management are as of 12.31.2016 and include consulting services for clients whose assets are valued at approximately $63bn.
Media Contact Ellen Cunningham Guggenheim Partners 212.518.9578 [email protected]
